+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Dialysance of Amino Acids and Related Substances

      , ,


      S. Karger AG

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The losses of amino acids and related compounds have been studied during hemodialysis of patients with the Kiil dialyzer and the Dow Hollow Fiber Artificial Kidney (HFAK). There was a linear relationship with close correlation for both direct dialysance (D<sub>d</sub>) and indirect dialysance (D<sub>p</sub>) between the two dialyzers, the HFAK being 31–46% more efficient than the Kiil dialyzer in removing these solutes. The volume from which the amino acids were extracted was found to be the plasma alone, since the ratio D<sub>p</sub>/D<sub>d</sub> was close to 1.00 for both dialyzers. A good correlation was found for both dialyzers between molecular weight and dialysance (r = 0.53,0.57) but the correlation was even closer between the diffusion coefficient in water and the dialysance of the solutes (r = 0.86, 0.89). The absolute losses of the amino acids during dialysis for short periods in the fasting state were extrapolated to 8 h, the usual duration of a dialysis. For the Kiil dialyzer extrapolated losses were sizeable (as percentage of minimal daily requirements) for only three essential amino acids: valine (36%), lysine (44%) and threonine (48%). With the HFAK the losses of all essential amino acids except phenylalanine and methionine were sizeable, the highest being for valine (59%), lysine (59%) and threonine (108%). The possible significance of these losses to patients on chronic dialysis are discussed.

          Related collections

          Author and article information

          S. Karger AG
          26 November 2008
          : 8
          : 5
          : 440-454
          University of California Medical Services and Northern California Artificial Kidney Center, San Francisco General Hospital, and the Life Sciences Division, Stanford Research Institute, Menlo Park, Calif.
          179948 Nephron 1971;8:440–454
          © 1971 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 15

          Cardiovascular Medicine, Nephrology


          Comment on this article